Author: CannabisNewsWire (CNW)

About CannabisNewsWire CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge. To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only) For more information please visit https://www.CannabisNewsWire.com Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

420 with CNW — Researchers Find Marijuana May Be Effective Against Parkinson’s Disease

Researchers have uncovered definite proof that cannabis can be effective at alleviating the symptoms of Parkinson’s disease. The neurodegenerative disorder, which was first identified in 1872 by James Parkinson, affects nearly one million Americans. Figures show that at least 6,000 individuals are diagnosed with the disorder every year.

The disease causes certain parts of the brain to degenerate, causing symptoms such as impaired coordination and balance, slow movements, muscle stiffness and tremors in the legs, hands, arms and jaws. More than a century after the disease was first identified, we still haven’t found an effective cure, relying instead on treatments that can reduce the symptoms and improve the quality of life of affected patients.

However, many of these medications tend to leave patients with several side effects, including low blood pressure, nausea, hallucinations, behavioral issues and involuntary movements.

A recent survey of German Parkinson’s patients has revealed that more than one-half of the participants saw benefits after taking part in cannabis clinical trials. The study, whose findings were reported in the “Journal of Parkinson’s Disease,” found that 54% of Parkinson’s patients who use certain cannabis strains tolerated the drug well and saw an overall positive impact. More than 40% said that cannabis treatment alleviated muscle cramps and pain while more than 20% reported that taking cannabis reduced anxiety, stiffness, tremors and restless legs as well as feeling cold.

The study’s lead researcher, Carsten Buhmann, noted that although patients with Parkinson’s disorder (PD) were interested in cannabis treatments, they often lacked relevant knowledge on cannabinoids and which ones they should take.

A different survey revealed that some PD patients already consume marijuana at least once a day. The survey was conducted by the Michael J. Fox Foundation (MJFF) via the Fox Insight platform, with researchers from the University of Colorado asking participants about the type of marijuana products they take, the amount of THC and CBD those products contained, how long they had been medicating with cannabis and their consumption frequency.

Of the nearly 1,900 patients who were polled, more than 70% said that they consume cannabis, usually orally, at least once a day. Almost 50% of the participants used high-CBD products, 15% took products with equal amounts of CBD and THC, and some weren’t sure about the type of marijuana products they consumed.

Plenty of the patients revealed that cannabis had helped to reduce their pain, agitation and anxiety, as well as helping with sleep.

Another survey from 2022 showed that PD patients who used high-THC products reported reductions in tremors, depression and nausea as well as improved appetite. Researchers from the 2022 survey concluded that cannabis showed promise as a natural treatment for Parkinson’s disease and called for more rigorous and controlled studies.

There are many more beneficial effects of marijuana that are yet to be documented by the scientific community, and you can bet that as these benefits are discovered, the market served by licensed companies such as Flora Growth Corp. (NASDAQ: FLGC) will continue to grow.

NOTE TO INVESTORS: The latest news and updates relating to Flora Growth Corp. (NASDAQ: FLGC) are available in the company’s newsroom at https://cnw.fm/FLGC

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

CannabisNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Poised with Strong In-Market Brand Portfolio, Cultivation and Export Capabilities

Flora Growth Corp. (NASDAQ: FLGC) recently reported that its board of directors had authorized the repurchase of up to $5 million of its outstanding common shares. “These recent developments highlight Flora management’s confidence in where the company is headed and its potential for growth as the year progresses. It also assures shareholders of the company’s commitment to driving shareholder value and exploring various opportunities to do so. As such, this only emphasizes Flora’s value as a good investment,” a recent article reads. “While making the announcement, Luis Merchan, Flora’s chairman and CEO, noted: ‘Flora continues to move assertively to execute its growth plans while simultaneously improving gross profit margins and reducing corporate expenses. We are confident in the company’s short, medium and long-term growth prospects based on our strong in-market brand portfolio together with our cultivation and export capabilities in life sciences research. The repurchase program affords us the opportunity to increase our ownership in our portfolio of high-quality brands through our shares, which in our view are trading well below NAV.’”

To view the full article, visit https://cnw.fm/HqK3B

About Flora Growth Corp.

Flora is building a connected, design-led collective of plant-based wellness and lifestyle brands delivering the most compelling customer experiences in the world, one community at a time. As the operator of one of the most extensive outdoor cannabis cultivation facilities, Flora leverages natural, cost-effective cultivation practices to supply cannabis derivatives to its commercial, house of brands and life sciences divisions. Visit www.FloraGrowth.com or follow @floragrowthcorp on social media for more information.

NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://cnw.fm/FLGC

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive SMS text alerts from CannabisNewsWire, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH-CBD Hypertension Study Completes Dosing with No Serious Adverse Events

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced that dosing with its DehydraTECH(TM)-processed cannabidiol (“DehydraTECH-CBD”) has been completed in its multi-week human clinical hypertension study HYPER-H21-4. According to the update, no serious adverse events have been reported as a result of the dosing. “We are extremely pleased that dosing has been completed on time in this multi-week clinical study without any serious adverse events having occurred,” said Chris Bunka, CEO of Lexaria Bioscience Corp. “Demonstrating a noteworthy safety and tolerability profile relative to conventional anti-hypertensive medications is one of Lexaria’s major goals with this program, and avoiding serious adverse events at clinically efficacious doses will be a primary requirement to achieve eventual regulatory marketing authorizations.”

To view the full press release, visit https://cnw.fm/LAvpE

About Lexaria Bioscience Corp.

Lexaria’s patented drug delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids, antiviral drugs, PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 25 patents granted, one patent allowed, and roughly 50 patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

To receive SMS text alerts from CannabisNewsWire, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

420 with CNW — NY Governor Announces $5m in Grants to Help Community Colleges Train Marijuana Workers

Recently, Gov. Kathy Hochul of New York announced that the state had allocated $5 million to community colleges for the improvement and development of programs and courses meant to help individuals secure jobs in the cannabis industry. Hochul stated that this initiative would help meet the demand for a skilled workforce in the burgeoning industry as well assist the administration in meeting its goal to ensure that there was equity in market opportunities.

The funding initiative will allocate $1 million each to a trio of community colleges in the State University of New York system and the remaining $2 million to one city University of New York community college. Each of these campuses is expected to partner with other community colleges in the state and will act as the marijuana education program lead.

The funds will be used for degree and nondegree eligible programs and courses, as well as stackable micro-credentials and credentials that will be developed to help the local cannabis businesses in the state to find qualified candidates.

In a press release, the governor stated that the state’s new marijuana industry was creating exciting opportunities, noting that the administration would ensure that individuals in the state who wanted careers in the flourishing industry could access the quality training they required to be successful. She added that inclusion and diversity are what made the state of New York a powerful and competitive asset, noting that they would also take steps to ensure that every person had the opportunity to participate in the marijuana industry.

The press release also stated that the selected colleges would serve social equity candidates as defined under the Office of Cannabis Management’s regulations. In addition to this, these institutions will also need to work with local cannabis businesses in their communities to help inform their marijuana curriculum. The Office of Cannabis Management and the Department of Labor in the state will also be required to connect businesses and individuals seeking jobs to these training programs. Once individuals have completed said programs, the Department of Labor will be tasked with assisting them with completing their resumes, preparing for job interviews and promoting career opportunities.

This initiative comes as regulators in the state work to develop and implement rules for the cannabis market, which is set to launch its adult-use marijuana retailers later this year.

The state of New York is one of many in the country that are working to advance cannabis legalization and decriminalization reforms so that licensed entities similar to Advanced Container Technologies Inc. (OTC: ACTX) can set up shop and serve clients in this space.

NOTE TO INVESTORS: The latest news and updates relating to Advanced Container Technologies Inc. (OTC: ACTX) are available in the company’s newsroom at https://cnw.fm/ACTX

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — House Democrats Urge Senators to Approve Cannabis Banking Bill

Since the advent of America’s fledgling cannabis industry, licensed marijuana businesses have been unable to access banking services. Since federal law classifies cannabis as a Schedule I controlled substance, banking institutions avoid partnering with state-legal cannabis businesses. This has made such businesses prime targets for robberies and burglaries because they are forced to operate on a cash-only basis and tend to have thousands of dollars on site.

House representatives have tried to pass cannabis banking regulations that would finally allow businesses in the state-legal cannabis industry to access much-needed banking services. However, these protections have failed to advance past the Senate more than five times even though Senate Majority Leader Chuck Schumer is an ardent believer in cannabis reform. Now that the midterms are fast approaching, a bipartisan group of representatives is urging the Senate to pass the SAFE Banking Act.

Introduced by Rep. Ed Perlmutter, the SAFE Banking Act would allow financial institutions to serve the state-legal cannabis industry without fear of federal reprisal. Even though the legislation has been advanced by the House seven times as either a standalone bill or as an amendment to larger legislation, it has repeatedly failed to get past the Senate.

Lead sponsor of the act, Perlmutter says lawmakers have been frustrated for quite a while over the Senate’s refusal to pass cannabis banking. He says that Senate lawmakers have to figure out what they want from a cannabis banking bill and what they can actually pass, which will ultimately require bipartisan discussions between Senate Democrats and Republicans.

Perlmutter is now trying to advance cannabis banking on two fronts: he is working to include cannabis banking language in the National Defense Authorization Act (ACT), and he is waiting for Schumer to finally unveil his long-anticipated cannabis reform bill. Schumer’s Cannabis Administration & Opportunity Act (CAOA) would decriminalize cannabis at the federal level and also contains criminal justice elements, but it has been delayed several times.

Schumer, who stated in the past that he would advance comprehensive cannabis reform with or without President Joseph Biden’s support, has stated repeatedly that cannabis reform with social equity components should advance before cannabis banking. Last September, he even revealed that several key senators had agreed not to advance marijuana banking reform before comprehensive legalization.

Even so, lawmakers from the House of Representatives are now increasing the pressure on their Senate counterparts to pass cannabis banking. Perlmutter emphasizes that Senators must act on a standalone cannabis banking bill that is currently on the floor of the Senate Banking Committee. Senators also have the option of adding cannabis banking language to the NDAA, he says. In this way, the industry and its leading actors such as American Cannabis Partners would have access to banking services, as do other state-legal industries.

NOTE TO INVESTORS: The latest news and updates relating to American Cannabis Partners are available in the company’s newsroom at https://cnw.fm/ACP

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Licensee Launches Ko Brand in Preparation to Deploy DehydraTECH CBD Products in Japan

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced that its exclusive* Japanese licensee, Premier Wellness Science Co. Ltd., officially launched the first generation of its new cannabidiol (“CBD”) products under the brand “Ko.” According to the update, the brand was launched for the Japanese consumer market on July 21, 2022. Premier will create its own e-commerce infrastructure and digital marketing campaigns in collaboration with its parent company, Premier Anti-Aging Co. Ltd., which is listed on the Tokyo Stock Exchange (4934:JP). The Ko brand will contain CBD and other botanical extracts and is focused on the endocannabinoid system and circadian rhythm to support the health and wellness of all people, highlighted by the concept of wellness for all. Following rigorous product development and formula optimization, Ko-branded products containing Lexaria’s DehydraTECH(TM) delivery technology are expected to be introduced during the second quarter of 2023.

To view the full press release, visit https://cnw.fm/xoiJD

About Lexaria Bioscience Corp.

Lexaria’s patented drug delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids, antiviral drugs, PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 25 patents granted plus a 26th patent allowed, as well as roughly 50 patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.

*The exclusive rights are subject to two previously issued licenses for use of DehydraTECH in Japan, which remain valid. Lexaria will not be issuing any further licenses in Japan for non-pharmaceutical cannabinoid products.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

To receive SMS text alerts from CannabisNewsWire, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

CannabisNewsBreaks – Advanced Container Technologies Inc. (ACTX) Notes Reports Indicating Agriculture May Be ‘Recession-Proof’ Space

Advanced Container Technologies (OTC: ACTX), the exclusive U.S. distributor of self-contained, automated, indoor “micro-farms” called GrowPods, is pointing to a new study indicating that agriculture may be “one of the most recession proof sectors” because despite economic conditions, people still need food. The Money Made report studied the performance of 12 different asset classes against the S&P 500 during three recent market crashes, concluding that agriculture came out on top overall, averaging returns that are at least 24% better than those of the S&P 500. The company also noted that Small Business Trends News reported that the agriculture industry is one of the most recession-proof sectors, stating that food is “not a luxury that can be put aside during difficult times, so businesses in this sector can continue to do well even during a recession.” In addition, the company quoted Farm Folio, observing that farming is a “wise route for diversification” because during recessions when the value of stocks, bonds and other investments fall, farming assets historically increase in value. According to the company’s release, its GrowPods, or modular hydroponic farms, can be placed virtually anywhere and can grow the equivalent of three acres of traditional farmland — all in an automated, controlled, pesticide-free environment.

To view the full press release, visit https://cnw.fm/CEjvX

About Advanced Container Technologies Inc.

Advanced Container Technologies is in the business of selling and distributing self-contained, automated, indoor “micro-farms” called GrowPods, along with related equipment and supplies. Additionally, the company designs and sells patented proprietary medical-grade plastic containers, known as the Medtainer(R), that store and grind pharmaceuticals, herbs, teas and other solids or liquids. For more information, visit the company’s website at www.AdvancedContainerTechnologies.com.

NOTE TO INVESTORS: The latest news and updates relating to ACTX are available in the company’s newsroom at https://cnw.fm/ACTX

About CannabisNewsWire

To receive SMS text alerts from CannabisNewsWire, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

420 with CNW — President Biden Reaffirms Pledge to Fulfill Cannabis Campaign Promises

A few months after President Joseph Biden assumed office, his administration passed a major infrastructure bill that, among other things, provided billions of dollars for the development of a nationwide network of public electric vehicle chargers, fulfilling a promise he had made while on the campaign trail. However, the administration has been slow to pass the cannabis reforms President Biden had promised while campaigning, with Biden failing to make a definitive public statement about marijuana policy in the year and a half since he entered the Oval Office.

After more than a year of silence on cannabis reforms, the president has now revealed that his administration is “working on” plans to meet his pledge to pardon and free people who are currently in prison due to cannabis-related offenses. It is the first time he has made a public statement about his administration’s plans to enact cannabis reform since he became the president.

While speaking to journalists on the White House lawn after he stepped off Marine One, Biden said that he didn’t think anyone should be incarcerated for using cannabis. Although he didn’t provide any specifics, the president said that his administration was currently working on a crime bill; press staff from the White House did not respond to further queries for clarification.

Despite dozens of states legalizing cannabis and generating billions of dollars in tax revenue, around 40,000 Americans are currently in prison for marijuana offenses.

According to Richard Bronson, founder and CEO of 70 Million, a staffing agency that serves people with criminal records, people with criminal records “go through hell” to find employment. He said that many of these individuals are men and women of color who, despite serving their time, are still penalized once they enter society. Furthermore, he said the fact that thousands of Americans are still imprisoned for activities that are now legal is an irony of gruesome proportions.

Since he took office, Biden has received several requests from advocates and lawmakers to exercise his executive powers and issue mass pardons for people who were convicted for nonviolent, cannabis-related offenses. His administration has received nearly a dozen letters from advocates, lawmakers and others who have been personally impacted by cannabis prohibition to pardon people who are still imprisoned for cannabis offenses,

The only action Biden has taken has been to grant clemency to dozens of people with nonviolent marijuana convictions on their records in April. Although his actions were lauded, they are still a far cry from the mass pardons advocates and lawmakers have been seeking.

To the cannabis industry and its leading actors, such as Cannabis Strategic Ventures Inc. (OTC: NUGS), concrete actions to implement the ending of prohibition or its facets carries more meaning than the current rhetoric to the effect that the matter is being considered.

NOTE TO INVESTORS: The latest news and updates relating to Cannabis Strategic Ventures Inc. (OTC: NUGS) are available in the company’s newsroom at http://cnw.fm/NUGS

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Malta, The Netherlands, Luxembourg and Germany Hold Joint Meeting on Cannabis Legalization

Officials from several European countries recently met to discuss the factors involved in legalizing adult-use cannabis amid a wave of cannabis reform across the region. The historic meeting is expected to be the first of several multilateral discussions and could be expanded to include other countries. The joint meeting involved representatives from The Netherlands, Malta, Germany and Luxembourg.

Advocates have lauded the meeting, stating that it is critical to cannabis reform in Europe by allowing member states to coordinate their marijuana regulations and dealing with any pushback from the United Nations (UN). As it stands, the UN currently bans member states from legalizing recreational cannabis. A joint statement from the countries involved reveals that although the meeting did not result in any major decisions, officials from the countries are aware that the current prohibitionist stance against cannabis is not a “tenable option.”

Consequently, countries with prohibitionist policies will have to review the available data on the short- and long-term impacts of prohibition and find ways to regulate cannabis. The statement notes that such joint meetings are crucial to sharing knowledge, experiences and best practices, as well as finding appropriate solutions to the issues that could hold back cannabis reform.

More specifically, the statement says that this “first multilateral exchange” was geared toward discussions for regulating marijuana for nonscientific and nonmedical issues. The countries involved say that the discussions are needed for a variety of reasons, including addressing the public health risks exacerbated by the illicit cannabis market and providing efficient ways for law enforcement to identify different types of cannabis products.

The joint statement also emphasized the need to review existing cannabis policies, especially considering recent cannabis legislative changes in other countries. There is also an urgent need to develop and strengthen social and health programs such as treatment, harm-reduction and prevention programs.

Luxembourg Minister of Justice Sam Tanson said in a separate statement that more than 50 years after the country criminalized drug use, it still bases its drug policy on repression. He said that statistics show that this approach has not been successful, underscoring the need for a new approach to dealing with drug-related behavior based on discussions with territories that have also pursued similar repression-based approaches with little success.

According to Luxembourg Deputy Prime Minister Paulette Lenert, cannabis policy across the region is sorely in need of a paradigm shift that is based on prevention and the reduction of drugs harms and risks via regulation rather than prohibition.

This viewpoint that prohibition is doing more harm than good is already strong in the United States, and the marijuana industry and its actors such as Prime Harvest Inc. look forward to the time when the prohibitionist machinery will be totally dismantled at a federal level.

NOTE TO INVESTORS: The latest news and updates relating to Prime Harvest Inc. are available in the company’s newsroom at https://cnw.fm/PRIME

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX) Receives Notice of Allowance of 26th Worldwide Patent

Lexaria, a global innovator in drug delivery technology, has developed the patented DehydraTECH(TM) technology which has been the subject of several issued patents
Recently, Lexaria reported it had been notified of the allowance of its 26th worldwide patent with a new patent to be granted in Japan
The patent is the fourth to be granted in Japan and the first patent issued from Lexaria’s seventh patent family
Lexaria also submitted a briefing book to the FDA to facilitate its upcoming pre-Investigational New Drug (“IND”) meeting with the agency

“We are extremely pleased to have received our first patent protecting our proprietary technology… I expect our intellectual property portfolio to continue to expand,” said Lexaria Bioscience (NASDAQ: LEXX) CEO Chris Bunka in an October 2016 press release announcing that the company had been issued U.S. Patent No. 9,474,725, Cannabinoid Infused Food and Beverage Compositions and Methods of Use Thereof, by the U.S. Patent and Trademark Office (“USPTO”) (https://cnw.fm/AxzvE).

Since receiving this patent, its first ever, which pertains to LEXX’s method of enhancing bioavailability and taste of specific cannabinoid lipophilic active agents in food products, the company has amassed an impressive portfolio worldwide that includes patents granted in India, Australia, Japan, the U.S., Mexico, and Europe, and is, in fact, still growing as its patent applications advance to granted patents. Lexaria is pursuing patent protection in over 40 countries and currently has roughly 50 pending patent applications globally (https://cnw.fm/zCxCK).

In a development that now pushes the number of granted patents worldwide to 26, Lexaria recently reported it had been notified of the allowance of a new patent to be granted in Japan, the fourth to be granted in that country. Entitled Lipophilic Active Agent Infused Compositions with Reduced Food Effect, this is the first patent issued from Lexaria’s seventh patent family and refers to tetrahydrocannabinol (“THC”) (https://cnw.fm/tGi2U).

The new patent acknowledges DehydraTECH(TM)’s ability to deliver active pharmaceutical ingredients (“APIs”) more efficiently, in a process known as absorption, regardless of the presence of food in the gastrointestinal system. Ordinarily, food impacts drug absorption by physically interacting with drugs, altering the pH, stimulating bile flow, slowing gastric emptying time, or increasing splanchnic blood flow (https://cnw.fm/jc21f). But DehydraTECH, Lexaria’s patented drug delivery technology, delivers drugs more consistently into the bloodstream regardless of this food effect. The drug delivery technology achieves this through its use of fatty acid oil.

Lexaria’s technology joins the API’s molecules in what is believed to be a “barbell-shaped” structure that allows the body to detect both molecules while enhancing taste and absorption. The body’s detection and natural processing of the long chain fatty acid is part of Lexaria’s clever patented process that also enhances the API absorption.

Bioavailability refers to both absorption levels and the time required to absorb. “In order to feel something quickly, you need to avoid something that’s known as fast-pass liver metabolism. When you eat food, it goes into your stomach, then it goes into your intestine, and then most of the nutrients go into your liver for filtration before they get into the bloodstream. That takes about an hour and a half, on average. But [using] our technology, we are able to divert the molecules away from the liver, and that allows you to get feelings or experiences in as little as 15 to 20 minutes,” Chris Bunka continued.

Meanwhile, Lexaria also reported it had submitted its briefing book to the U.S. Food and Drug Administration (“FDA”). This documentation will facilitate a pre-Investigational New Drug (“IND”) meeting that LEXX had requested in an early June letter to the FDA. The FDA provided a target date of July 30, 2022, for a meeting or comments.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.